Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
McKesson
Deloitte
Merck
Cipla

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,696,162

« Back to Dashboard

Summary for Patent: 7,696,162
Title:Zinc-free and low-zinc insulin preparations having improved stability
Abstract:The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Inventor(s): Boderke; Peter (Frankfurt am Main, DE)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:12/285,464
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,696,162
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Drugs Protected by US Patent 7,696,162

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021629-001 Apr 16, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS ➤ Sign Up
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021629-002 Dec 20, 2005 DISCN Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS ➤ Sign Up
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,696,162

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 14 178Mar 23, 2001

International Family Members for US Patent 7,696,162

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033059 ➤ Sign Up
Argentina 096376 ➤ Sign Up
Austria 497777 ➤ Sign Up
Australia 2002302409 ➤ Sign Up
Brazil 0208210 ➤ Sign Up
Brazil PI0208210 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Fish and Richardson
Teva
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.